TMO - Thermo Fisher Scientific Inc Stock Analysis
Thermo Fisher Scientific Inc (TMO) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 214.46B, generates annual revenue of 46.34B, and reports net income of 6.97B. As of the latest data, the stock is trading at 580.02 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The dividend yield (0.32%) is modest, often associated with growth-oriented companies. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at Buy (4.11), indicating current market sentiment. Institutional ownership is reported at 92.26%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 29.20%, trading within a 52-week range of 435.27 - 643.99.
TMO - Thermo Fisher Scientific Inc
580.02
Analyst Consensus
Buy 4.11
TMO – Analyst Rating Summary
- Strong Buy: 11
- Buy: 18
- Hold: 7
- Sell: 0
- Strong Sell: 0
- Total Analysts: 36
| Index: | S&P 500 | P/E: | 31.20 | EPS (ttm): | 18.59 | Insider Own: | 0.26% | Shs Outstand: | 369.75M | Perf Week: | 0.56% |
| Market Cap: | 214.46B | Forward P/E: | 21.15 | EPS next Y: | 27.43 | Insider Trans: | -1.72% | Shs Float: | 368.80M | Perf Month: | 13.70% |
| Income(ttm): | 6.97B | PEG: | 2.17 | EPS next Q: | 6.41 | Inst Own: | 92.26% | Short Float: | 1.44% | Perf Quarter: | 22.64% |
| Revenue(ttm): | 46.34B | P/S: | 4.63 | EPS this Y: | 9.78% | Inst Trans: | -2.72% | Short Ratio: | 2.22 | Perf Half Y: | 2.62% |
| Book/sh: | 142.47 | P/B: | 4.07 | EPS next Y: | 9.25% | ROA: | 6.50% | Short Interest: | 5.30M | Perf Year: | 29.20% |
| Cash/sh: | 11.02 | P/C: | 52.63 | EPS next 5Y: | 9.74% | ROE: | 13.51% | 52W Range: | 435.27 - 643.99 | Perf YTD: | 0.10% |
| Dividend Est.: | 1.85 (0.32%) | P/FCF: | 29.31 | EPS past 3/5Y: | 0.18% 2.11% | ROIC: | 7.59% | 52W High: | 643.99 -9.93% | Beta: | 0.84 |
| Dividend TTM: | 1.80 (0.31%) | Quick Ratio: | 1.18 | Sales past 3/5Y: | -0.27% 6.70% | Gross Margin: | 40.19% | 52W Low: | 435.27 33.26% | Perf 5Y: | 7.77% |
| Dividend Ex-Date: | Sep 15, 2026 | Current Ratio: | 1.55 | EPS Y/Y TTM: | 7.47% | Oper. Margin: | 19.09% | RSI (14): | 67.59 | Volatility: | 2.46% 2.69% |
| Employees: | 125000 | Debt/Eq: | 0.81 | Sales Y/Y TTM: | 7.23% | Profit Margin: | 15.04% | Recom: | 1.53 | Target Price: | 639.04 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.74 | EPS Q/Q: | 9.38% | Payout: | 9.70% | Rel Volume: | 0.72 | Prev Close: | 577.83 |
| Sales Surprise: | 2.46% | EPS Surprise: | 5.43% | Sales Q/Q: | 10.49% | Earnings: | Jul 23 BMO | Avg Volume: | 2.38M | Price: | 580.02 |
| SMA20: | 4.72% | SMA50: | 12.67% | SMA200: | 9.12% | Undervalued: 10.18% | Volume: | 1,719,409 | Change: | 0.38% | |
Graham Classic formula value: 467.07
(P/E=8 * 1g) Min value: 296.13
(current P/E * 2g) Max value: 846.0
Average value: 536.4
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers products and services to customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of disease. The Analytical Instruments segment offers instruments and supporting consumables, software and services. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products to healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. The company was founded in July 1956 and is headquartered in Waltham, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.